Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin

AAPS PharmSciTech

Volumn 8, Issue 3, 2007, Pages

  Kanagale, Pritam ^a   Lohray, Braj Bhushan ^a   Misra, Ambikanandan ^b   Davadra, Prakash ^a   Kini, Rajesh ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Cellulose acetate; Osmogent; Osmotic system; Oxybutynin; Pore former

Indexed keywords

CELLULOSE ACETATE; DRUG ADDITIVE; MACROGOL 400; OXYBUTYNIN; POLYMER; SORBITOL; WATER; EXCIPIENT; MANDELIC ACID DERIVATIVE;

ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISSOLUTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HYDRODYNAMICS; IN VITRO STUDY; MOLECULAR WEIGHT; OSMOTIC PUMP; PH; POROSITY; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; CHEMISTRY; DELAYED RELEASE FORMULATION; OSMOTIC PRESSURE; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; TABLET;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MANDELIC ACIDS; MICROSCOPY, ELECTRON, SCANNING; OSMOTIC PRESSURE; POROSITY; SOLUBILITY; TABLETS;

EID: 34547129342     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0803051     Document Type: Article

References (16)

1. Speers M, Bonnano C. Economic aspects of controlled drug delivery. In: Mathiowitz E, ed. Encyclopedia of Controlled Drug Delivery. New York, NY Wiley; 1999:341-347.
2. Santus G, Baker WR. Osmotic drug delivery: a review of patent literature. J Control Release. 1995;35:1-21.
3. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64: 1987-1991.
4. Zentner GM, McClelland GA, Sutton SC. Controlled porosity solubility- and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J Control Release. 1991;16:237-244.
5. Zentner M, Rork GS, Himmelstein KJ. Osmotic flow through controlled porosity films: an approach to delivery of water-soluble compounds. J Control Release. 1985;2:217-229.
6. Zentner GM, Rork GS, Himmelstein KJ, inventors. Controlled porosity osmotic pump. US patent 4 968 507. November 6, 1990.
7. Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric-membrane tablet coatings for osmotic drug delivery. J Control Release. 1995;35:127-136.
8. Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999;21:634-642.
9. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988;35:515-520.
10. Brunton LL, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY. McGraw-Hill; 2006.
11. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999;39:289-296.
12. Monograph 7089. Oxybutynin Chloride. In: Budavari S, ed. The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co; 1996.
13. Byrn SP, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001;48:115-136.
14. Verma RK, Kaushal AM, Garg S. Development and evaluation of extended release forinulations of isosorbide mononitrate based on osmotic technology. Int J Pharm. 2003;263:9-24.
15. Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J Control Release. 1985;1:269-282.
16. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64-74.